Adverum Biotechnologies, Inc. (ADVM) — Financial statements
Income statement, balance sheet, and cash flow for Adverum Biotechnologies, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1↓72.2% | 4 | 0.00↓100.0% | 8 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 4 | |
| Gross Profit | 1↓72.2% | 4 | 0.00↓100.0% | 8↑280.4% | -4 | |
| Operating Expenses | ||||||
| R&D Expenses | 77↓0.6% | 77↓21.9% | 99↑11.3% | 89↑21.7% | 73 | |
| General & Administrative Expenses | 63↑14.6% | 55↓4.8% | 58↓10.2% | 64↑44.4% | 45 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 63↑14.6% | 55↓4.8% | 58↓10.2% | 64↑44.4% | 45 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -4 | |
| Operating Expenses | 140↑5.7% | 133↓15.7% | 157↑2.3% | 154↑35.0% | 114 | |
| Total Costs & Expenses | 140↑5.7% | 133↓15.7% | 157↑2.3% | 154↑30.2% | 118 | |
| Operating Results | ||||||
| Operating Income | -139↓7.9% | -129↑17.9% | -157↓7.5% | -146↓23.9% | -118 | |
| Depreciation & Amortization | 4↓35.3% | 6↓13.5% | 7↑40.5% | 5↑11.7% | 4 | |
| EBITDA | -136↓9.9% | -123↑18.1% | -151↓6.5% | -141↓26.1% | -112 | |
| EBIT | -139↓7.9% | -129↑17.9% | -157↓7.5% | -146↓25.5% | -116 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -2 | |
| Other Income / Expenses | 8↑43.2% | 6↑115.0% | 3↑359.3% | 0.58↓62.6% | 2 | |
| Income Before Tax | -131↓6.3% | -123↑20.2% | -154↓6.1% | -146↓25.0% | -116 | |
| Income Tax Expense | 0.00↑100.0% | -1↓1556.8% | 0.07 | 0.00↓100.0% | 1 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -131↓7.2% | -122↑21.0% | -155↓6.2% | -146↓23.9% | -118 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -131↓7.2% | -122↑21.0% | -155↓6.2% | -146↓23.9% | -118 | |
| Bottom-Line Net Income | -131↓7.2% | -122↑21.0% | -155↓6.2% | -146↓23.9% | -118 | |
| EPS (Basic) | -6.62↓227.7% | -2.02↑24.3% | -2.67↓80.4% | -1.48↓17.5% | -1.26 | |
| EPS (Diluted) | -6.62↓227.7% | -2.02↑24.3% | -2.67↓80.4% | -1.48↓17.5% | -1.26 | |
| Weighted Average Shares | 20↓65.9% | 58↑0.0% | 58↓41.1% | 98↑5.5% | 93 | |
| Weighted Average Diluted Shares | 20↓65.9% | 58↑0.0% | 58↓41.1% | 98↑5.4% | 93 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.